Record: 1

03/01/2024

Daily Note

Pages: 10

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 25.00

Record: 2

02/28/2024

Company Report

Pages: 8

Focus Turns to Orphan Lung Pipeline Afrezza w/ Tyvaso DPI Launch Underway

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 25.00

Record: 3

01/04/2024

Company Report

Pages: 7

Tyvaso DPI Royalty Monetization Magnitude Shines Light on Valuation Disconnect, in Our View; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Record: 4

01/03/2024

Company Report

Pages: 9

Tyvaso DPI Royalty Deal Pads Balance Sheet, Underscores Blockbuster Potential

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Record: 5

01/03/2024

Daily Note

Pages: 7

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Record: 6

12/21/2023

Daily Note

Pages: 5

Federal Circuit Affirms ''793 PTAB Decision; Tyvaso DPI''s Dominance to Persist

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 5.00

Record: 7

11/09/2023

Daily Note

Pages: 19

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Record: 8

11/08/2023

Company Report

Pages: 6

First-Time Profitability Milestone; Growth and Execution Across the Business; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Record: 9

11/08/2023

Company Report

Pages: 8

Q3: Tyvaso DPI Continues to Drive Growth; Orphan Drug Pipeline Trials in H1:24

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 12.50

Record: 10

10/10/2023

Daily Note

Pages: 8

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Record: 11

10/09/2023

Company Report

Pages: 21

Don''t Call It a Comeback...Initiating at OP and $10 PT

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 35.00

Record: 12

10/09/2023

Daily Note

Pages: 5

REMINDER: Wedbush PacGrow Healthcare Bus Trip to Tyvaso DPI Facility in CT

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 5.00

Record: 13

10/09/2023

Company Report

Pages: 21

Don''t Call It A Comeback...Initiating at OP and $10 PT

Provider: Wedbush Securities Inc.

Analyst: ARGYRIDES A

Price: 35.00

Record: 14

08/14/2023

Company Report

Pages: 6

Breakeven Secured Ahead of Schedule; Tyvaso DPI Outperforming; Raise to $7.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Record: 15

05/11/2023

Company Report

Pages: 6

On Cusp of Positive Cash Flow; Material Upside From Current Business Alone, Plus Pipeline Optionality; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Record: 16

02/27/2023

Company Report

Pages: 6

4Q22: Tyvaso DPI Impressive Launch Ramp Continues; Afrezza Outperforming; Raise to $7 Before Adding Pipeline Value

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Record: 17

11/09/2022

Company Report

Pages: 6

3Q22: Cooking With Gas as Tyvaso DPI Jumps Out of the Gates; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Record: 18

06/01/2022

Company Report

Pages: 6

Breathing Easy With Tyvaso DPI Approval and V-Go Accretive Bolt-On Product Acquisition

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Record: 19

02/28/2022

Company Report

Pages: 8

Tyvaso DPI Safety Fear and Stock Pullback Likely an Overreaction; Reiterate Buy; Tweak Target to $6 on Lower Afrezza

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Record: 20

11/11/2021

Company Report

Pages: 8

3Q21: Expect TyvasoDPI Approval and Launch by Mid-2022, While Partner Grows Opportunity in the Meantime; Raise to $6.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50